Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy - Yakushijin, Yoshihiro; Shikata, Hisaharu; Takaoka, Ikue; Horikawa, Tamami; Takeuchi, Kazuhito; Yamanouchi, Jun; Azuma, Taichi; Narumi, Hiroshi; Hato, Takaaki; Yasukawa, Masaki (International journal of clinical oncology, 2011)
Keywords: Aged; Antibiotics, Antineoplastic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Blood diseases; Cancer Research; Chemotherapy; Cost-benefit; Cost-Benefit Analysis; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Drug Administration Schedule; Drug dosages; Drug therapy; Febrile neutropenia (FN); Female; Fever - blood; Fever - drug therapy; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - economics; Granulocyte colony-stimulating factors (G-CSF); Health care expenditures; Humans; Lenograstim; Leukocytes - drug effects; Lymphoma; Lymphoma, Large B-Cell, Diffuse - blood; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - economics; Male; Medicine; Medicine & Public Health; Middle Aged; Neutropenia - blood; Neutropenia - drug therapy; Neutropenia - economics; Neutrophils - drug effects; Non-Hodgkin lymphoma (NHL); Oncology; Original Article; Prednisone - administration & dosage; Prednisone - adverse effects; R-CHOP; Recombinant Proteins - administration & dosage; Recombinant Proteins - economics; Risk factors; Surgical Oncology; Vincristine - administration & dosage; Vincristine - adverse effects; Granulocyte colony-stimulating factors (G-CSF); Cost-benefit; R-CHOP; Non-Hodgkin lymphoma (NHL); Febrile neutropenia (FN)